Chief Executive Officer, Valneva
Appears in 1 story
Preparing for regulatory submissions alongside Pfizer
The last Lyme disease vaccine was pulled from the market in 2002 after unfounded safety fears destroyed demand. Twenty-four years later, Pfizer and French biotech Valneva announced that their replacement candidate showed 73% efficacy in a Phase 3 trial of over 9,000 participants, and said they will seek Food and Drug Administration (FDA) approval this year with a possible launch in late 2027.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
